HORIZON PHARMA

For us, it's personal

INVESTOR FACT SHEET

We are a biopharmaceutical company focused on making a powerful difference for patients, their caregivers and physicians by researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. For us, it's personal: By living up to our own potential, we are helping others live up to theirs.

OUR STRATEGY

Drive shareholder value by capitalizing on our defining strengths and generating high growth and profitability from our rare disease medicines

Successful and proven commercial execution that optimizes the growth trajectory of our acquired medicines

Significantly Improved Growth

KRYSTEXXA® pegloticase

KRYSTEXXA Net Sales

Uniquely strong in-house business development capability with a proven track record of execution

Recent Acquisitions

River Vision Development Corp.
May 2017
*Added **teprotumumab,** a late-stage development biologic, to our clinical development pipeline*

Raptor Pharmaceutical Corp.
October 2016
*Added **PROCYSBI®** and **QUINSAIR™,** both rare disease medicines, to our Orphan business unit*

Crealta Holdings LLC
January 2016
*Added **KRYSTEXXA®**, a rare disease medicine for uncontrolled gout, to our Rheumatology business unit*

Growing pipeline of differentiated and clinically relevant medicines with a focus on rare diseases

Driving Additional Growth With Our Rare Disease Focused Pipeline

MEDICINE/ CANDIDATE	DESCRIPTION	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	POST MARKET
KRYSTEXXA®	• TRIPLE trial: tolerization and immunomodulation* • RECIPE trial: immunomodulation* • MIRROR: KRYSTEXXA + methotrexate					●
RAYOS®	• RIFLE trial: lupus*					●
RAVICTI®	• Label expansion: birth to 2 months					●
HZN-001 (teprotumumab)(2)	• OPTIC trial: Phase 3 confirmatory • OPTIC-X trial: Phase 3 extension				●	
HZN-003	• Optimized uricase and optimized PEGylation for uncontrolled gout	●				
PASylation(3)	• Optimized uricase and PASylation for uncontrolled gout	●				

● Rare disease *Investigator-initiated trial

 – See reverse for footnotes

Purposeful Transition to Rare Disease Medicines Company

2013:

2 Medicines;
Net Sales of $74M



2017:

11 Medicines, 6 for Rare Diseases;
Net Sales of $1.06B



Orphan and Rheumatology Segment is Generating Strong Net Sales Growth



Rheumatology and Orphan Annual Net Sales ($M)

Executive Management

Timothy P. Walbert
Chairman, President and Chief Executive Officer

Brian K. Beeler
Executive Vice President, General Counsel

Robert F. Carey
Executive Vice President, Chief Business Officer

Michael A. DesJardin
Executive Vice President, Technical Operations

George P. Hampton
Executive Vice President, Primary Care Business Unit

Paul W. Hoelscher
Executive Vice President, Chief Financial Officer

Vikram Karnani
Executive Vice President, Chief Commercial Officer

David G. Kelly
Executive Vice Prsident, Company Secretary and Managing Director, Ireland

Irina P. Konstantinovsky
Executive Vice President, Chief Human Resources Officer

Shao-Lee Lin, M.D., Ph.D.
Executive Vice President, Head of R&D and Chief Scientific Officer

Barry J. Moze
Executive Vice President, Chief Administrative Officer

Jeffrey W. Sherman, M.D., FACP
Executive Vice President, Chief Medical Officer

Board of Directors

Timothy P. Walbert
Chairman, President and Chief Executive Officer

Michael Grey
Lead Independent Director

Liam Daniel

Jeff Himawan, Ph.D.

Ronald Pauli

Gino Santini

James Shannon, M.D.

H. Thomas Watkins

Pascale Witz

Key Figures

2017 Net Sales:	$1.06B
Closing Share Price (8/8/18):	$20.12
Market Capitalization (8/8/18):	$3.4B
Ordinary Shares Outstanding (6/29/18):	166.6M
Global Employees (12/31/17):	~1,035

For safety information, see product websites:

www.ACTIMMUNE.com
For BUPHENYL: www.horizonpharma.com
www.DUEXIS.com
www.KRYSTEXXA.com
www.MIGEROT.com
www.PENNSAID.com
www.PROCYSBI.com
www.RAVICTI.com
www.RAYOSrx.com
www.VIMOVO.com

Corporate Headquarters	U.S. Operations	Investor Relations Contacts		Corporate Media Contact	Ireland Media Contact
Connaught House, 1st Floor 1 Burlington Road Dublin 4, Ireland DO4 C5Y6 +353 1 772 2100	150 S Saunders Road Lake Forest, IL 60045 +1 224 383 3000	**Tina Ventura** investor-relations@horizonpharma.com	**Ruth Venning** investor-relations@horizonpharma.com	**Geoffrey Curtis** media@horizonpharma.com	**Ray Gordon** ray@gordonmrm.ie

(1) Horizon Pharma estimate. (2) Teprotumumab is a fully human monoclonal antibody (mAb) IGF-1R inhibitor for moderate-to-severe thyroid eye disease (TED). (3) Collaborative agreement.
MIRROR: **M**ethotrexate to **I**ncrease **R**esponse **R**ates in Patients with Uncontrolled G**O**ut **R**eceiving KRYSTEXXA. MIRROR is scheduled to start enrollment in 4Q'18. RECIPE: **RE**du**C**ing **I**mmunogenicity to **P**egloticas**E**. TRIPLE: **T**olerization **R**educes **I**ntolerance to **P**egloticase and Prolongs the Urate **L**owering **E**ffect. RIFLE: **R**AYOS (delayed release prednisone) **I**nhibits **F**atigue in **L**upus **E**rythematosus. OPTIC: Treatment of Graves' **O**rbitopathy (Thyroid Eye Disease) to Reduce **P**roptosis with **T**eprotumumab **I**nfusions in a Randomized, Placebo-Controlled, **C**linical Study.

This fact sheet is a summary of more detailed disclosure that can be found in Horizon's filings with the U.S. Securities and Exchange Commission and its press releases. This fact sheet contains forward-looking statements that involve significant risks and uncertainties, discussion of which can be found in Horizon Pharma's most recent forms 10-K, 10-Q, and 8-K. Horizon does not undertake any obligation to update any information in this document.